BioMarin Pharmaceutical Inc. (BMRN) Stock Price & Analysis
BioMarin Pharmaceutical Inc. (BMRN) closed at USD 56.63 on Thursday, October 22, 2026, up 2.57% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 55.21; the Oct 22, 2026 session ranged USD 55.02–56.91 on volume of 2,396,855 shares. Market capitalization is $10.96B, with a 52-week range of USD 49.26–70.98 (NMS). Source: Nexqual, retrieved October 23, 2026 at 09:27 UTC.
Also available as compact Markdown for AI agents: nexqual.com/BMRN.md
Key facts (BMRN)
- Last four reported quarters (through Jun 30, 2026): revenue $3.41B, net income $73.0M (2.1% margin), free cash flow $738M (SEC filings).
- 3 of 80 tracked superinvestors hold BMRN (13F, Q2 2026): 0 new, 2 added, 1 reduced, 0 unchanged.
- Total return with dividends: 1Y +3.8% vs S&P 500 +14.9%; 5Y -23.2% vs S&P 500 +80.3%.
- Next earnings: 2026-10-26, EPS estimate USD -0.11, revenue estimate $1.02B.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (BMRN)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $1.85B | $2.10B | $2.42B | $2.85B | $3.22B | $3.41B |
| Gross profit | $1.38B | $1.59B | $1.89B | $2.27B | $2.50B | — |
| Operating income | -$82.3M | $161M | $186M | $484M | $409M | $149M |
| Net income | -$64.1M | $142M | $168M | $427M | $349M | $73.0M |
| EPS (diluted) | -$0.35 | $0.75 | $0.87 | $2.21 | $1.80 | — |
| Free cash flow | $209M | $54.9M | $62.6M | $487M | $725M | $738M |
| Gross margin | 74.5% | 76.0% | 78.0% | 79.7% | 77.7% | — |
| Operating margin | -4.5% | 7.7% | 7.7% | 17.0% | 12.7% | 4.4% |
| Net margin | -3.5% | 6.8% | 6.9% | 15.0% | 10.8% | 2.1% |
| Revenue growth | -0.8% | +13.5% | +15.4% | +18.0% | +12.9% | — |
| Cash + short-term investments | $1.01B | $1.29B | $1.07B | $1.14B | $1.56B | — |
| Total debt | $1.08B | $1.08B | $593M | $595M | $597M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (BMRN)
P/E at fiscal year-ends: Dec 2025 33.6x, Dec 2024 30.3x, Dec 2023 110.2x.
Superinvestors (SEC 13F-HR, Q2 2026) (BMRN)
3 of 80 tracked investors hold BMRN. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Viking Global | Viking Global Investors | 1.24% | $436M | Added +7.8% |
| Torray Funds | 0.60% | $4.4M | Reduced -0.6% | |
| Dodge & Cox Funds | Dodge & Cox | 0.44% | $849M | Added +1.9% |
Analysts (BMRN)
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-21 | Morgan Stanley | Target lowered | Overweight | $124 → $122 |
| 2026-10-20 | JP Morgan | Target raised | Overweight | $86 → $87 |
| 2026-10-20 | Cantor Fitzgerald | Reiterated | Overweight | $86 |
| 2026-10-14 | Barclays | Target raised | Overweight | $111 → $114 |
| 2026-09-10 | HC Wainwright & Co. | Reiterated | Neutral | $60 |
| 2026-09-01 | Piper Sandler | Target raised | Overweight | $88 → $90 |
| 2026-08-31 | Jefferies | Target raised | Buy | $104 → $105 |
| 2026-08-31 | HC Wainwright & Co. | Target raised | Neutral | $59 → $60 |
| 2026-08-19 | BMO Capital | Initiated | Outperform | $98 |
| 2026-08-18 | HC Wainwright & Co. | Target lowered | Neutral | $60 → $59 |
| 2026-08-17 | Piper Sandler | Target raised | Overweight | $82 → $88 |
| 2026-08-17 | Barclays | Target raised | Overweight | $105 → $111 |
Total return (dividends reinvested) (BMRN)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +3.8% | -23.2% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +3.8% | -5.1% |
| Volatility (annualized) | 34.7% | 30.2% |
| Max drawdown | -22.6% (Aug 2026→Oct 2026) | -56.1% (Jan 2023→Nov 2025) |
Companies that name BMRN in their SEC reports
| Relationship to BMRN | Company | Filing | Sentence |
|---|---|---|---|
| partner | SPRUCE BIOSCIENCES, INC. (SPRB) | 10-K Mar 9, 2026 | “License Agreement with BioMarin Pharmaceutical, Inc.” |
| partner | Camp4 Therapeutics Corp (CAMP) | 10-K Mar 5, 2026 | “In September 2024, we entered into a Collaboration and License Agreement (the "BioMarin Agreement") with BioMarin Pharmaceutical Inc. ("BioMarin"), pursuant to which we and BioMarin agreed to collaborate with respect to the research and discovery of regulatory RNA-targeting ASOs using our proprietary RAP Platform to modulate the expression of two undisclosed genetic targets under two distinct programs.” |
| partner | Sarepta Therapeutics, Inc. (SRPT) | 10-K Mar 2, 2026 | “Under the terms of the License Agreement, we were required to pay the BioMarin Parties an up-front payment of $15.0 million” |
BMRN analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-0.11 | $1.49 | -107.5% | $1.02B | 13 |
| Next quarter (ends Dec 2026) | $1.69 | $1.73 | -2.7% | $1.14B | 11 |
| Current fiscal year (ends Dec 2026) | $3.51 | $4.93 | -29.0% | $3.92B | 14 |
| Next fiscal year (ends Dec 2027) | $6.42 | $6.39 | +0.4% | $4.50B | 13 |
BMRN options: expected move
Options price a move of about ±9.7% (±$5.50) by Nov 20, 2026, which includes earnings on Oct 26, 2026.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 28 | 42.6% | ±9.7% |
| Dec 18, 2026 | 56 | 35.0% | ±11.1% |
| Jan 15, 2027 | 84 | 36.4% | ±14.0% |
| Apr 16, 2027 | 175 | 36.1% | ±19.9% |
30-day implied volatility 37.1% vs 25.8% realized over the last 30 trading days. Put/call ratio (volume) 0.22. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 23, 2026 at 09:27 UTC)
| Price | USD 56.63 |
|---|---|
| Change | ▲ 2.57% (up) |
| Previous Close | USD 55.21 |
| Open | USD 55.4 |
| Day Range | USD 55.02 – 56.91 |
| 52-Week Range | USD 49.26 – 70.98 |
| Volume | 2,396,855 shares |
| Market Cap | $10.96B |
| Exchange | NMS |
Technical Analysis (BMRN)
Nexqual's technical model rates BMRN "SELL" based on 1 bullish and 4 bearish signals across 127 daily candles, as of October 23, 2026 at 09:27 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 42.19 (neutral) |
| vs SMA50 | Below (USD 61.97) |
| MACD | -1.8 (negative) |
Earnings (BMRN)
| Next Earnings Date | 2026-10-26 |
|---|---|
| EPS Estimate | USD -0.11 |
| Revenue Estimate | $1.02B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 1.2 vs est 0.95 ▲ beat |
| 2026-03-31 | USD 0.76 vs est 0.91 ▼ miss |
| 2025-12-31 | USD 0.46 vs est 0.56 ▼ miss |
| 2025-09-30 | USD 0.12 vs est 0.34 ▼ miss |
Source: Nexqual, October 23, 2026 at 09:27 UTC.
Financials & Fundamentals (BMRN)
| Total Revenue | $3.41B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +19.90% |
| Gross Margin | +50.97% |
| Operating Margin | +21.16% |
| Profit Margin | +2.14% |
| ROE | +1.18% |
| Debt / Equity | 0.66 |
| Current Ratio | 2.39 |
| Total Cash | $874.00M |
| Total Debt | $4.20B |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | $738.18M (21.7% of revenue) |
Source: Nexqual, October 23, 2026 at 09:27 UTC.
Financial Health Score (BMRN)
Nexqual rates BioMarin Pharmaceutical Inc.'s overall financial health "Solid" across five dimensions, as of October 23, 2026 at 09:27 UTC.
| Growth | Solid — Revenue +13% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 51%, operating 21% (last 12 months) |
| Balance Sheet | Strong — $874M cash and investments vs $4.19B debt (Jun 2026, SEC) |
| Cash Flow | Strong — FCF $738M (last 4 quarters to Jun 2026, SEC), 22% margin |
| Efficiency | Weak — ROE 1%, ROA 3.3% |
Ownership (BMRN)
| Insider Ownership | +0.34% |
|---|---|
| Institutional Ownership | +103.29% |
| Shares Outstanding | 193.57M |
| Float | 192.63M |
| Short % of Float | +5.97% |
Source: Nexqual, October 23, 2026 at 09:27 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| MDGL | Madrigal Pharmaceuticals, Inc. | USD 453.34 | ▼ 1.01% |
| TECH | Bio-Techne Corp | USD 72.62 | ▼ 0.03% |
| PCVX | Vaxcyte, Inc. | USD 62.85 | ▼ 0.6% |
| TWST | Twist Bioscience Corporation | USD 135.47 | ▼ 9.16% |
| KRYS | Krystal Biotech, Inc. | USD 320.13 | ▼ 0.63% |
| KYMR | Kymera Therapeutics, Inc. | USD 110.85 | ▼ 1.58% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:27 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt